CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.

View All HCPCS Sections

• Q0035

  Cardiokymography

• Q0081

  Infusion therapy, using other than chemotherapeutic drugs, per visit

• Q0083

  Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit

• Q0084

  Chemotherapy administration by infusion technique only, per visit

• Q0085

  Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit

• Q0091

  Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory

• Q0092

  Set-up portable x-ray equipment

• Q0111

  Wet mounts, including preparations of vaginal, cervical or skin specimens

• Q0112

  All potassium hydroxide (koh) preparations

• Q0113

  Pinworm examinations

• Q0114

  Fern test

• Q0115

  Post-coital direct, qualitative examinations of vaginal or cervical mucous

• Q0138

  Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

• Q0139

  Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)

• Q0144

  Azithromycin dihydrate, oral, capsules/powder, 1 gram

• Q0155

  Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0161

  Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0162

  Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0163

  Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen

• Q0164

  Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0166

  Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

• Q0167

  Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0169

  Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0173

  Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0174

  Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0175

  Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0177

  Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0180

  Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

• Q0181

  Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

• Q0220

  Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

• Q0221

  Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg

• Q0222

  Injection, bebtelovimab, 175 mg

• Q0224

  Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg

• Q0235

  Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg

• Q0237

  Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg

• Q0238

  Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg

• Q0239

  Injection, bamlanivimab-xxxx, 700 mg

• Q0240

  Injection, casirivimab and imdevimab, 600 mg

• Q0243

  Injection, casirivimab and imdevimab, 2400 mg

• Q0244

  Injection, casirivimab and imdevimab, 1200 mg

• Q0245

  Injection, bamlanivimab and etesevimab, 2100 mg

• Q0247

  Injection, sotrovimab, 500 mg

• Q0249

  Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg

• Q0477

  Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only

• Q0478

  Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type

• Q0479

  Power module for use with electric or electric/pneumatic ventricular assist device, replacement only

• Q0480

  Driver for use with pneumatic ventricular assist device, replacement only

• Q0481

  Microprocessor control unit for use with electric ventricular assist device, replacement only

• Q0482

  Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only

• Q0483

  Monitor/display module for use with electric ventricular assist device, replacement only

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.